Formulation of Verapamil Hydrochloride Pellets by ExtrusionSpheronization Technology

The objective of this study was to prepare and evaluate sustained release pellets of Verapamil Hydrochloride by using Extrusion - Spheronization method. The different formulations were prepared using HPMC, Dicalcium phosphate as synthetic polymers and MCC as spheronizing aid. Verapamil Hydrochloride is a phenylalkylamine calcium channel blocker which is used to treat high blood pressure. Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. It works by relaxing blood vessels so blood can flow more easily. Verapamil is also used in angina pectoris. The formulated pellets were evaluated for various parameters like flow properties like Angle of repose, Bulk density and Tapped density, Carr’s index, Hausner’s ratio, drug content, in vitro drug release study. FTIR study confirmed the drug - polymer compatibility. The in vitro drug release of Verapamil Hydrochloride pellets was compared with that of marketed formulation. The three formulations were prepared using synthetic polymers HPMC, Dicalcium phosphate. The formulation F1 shows sustained release at end of 8 hrs was found to be 93.37±0.37%. The drug content was found to be in the range of 80.98±0.08% to 93.37±0.03%. It can be concluded that the developed formulation can be effective formulation with improved efficacy, promised release and patient compliance. Finally, we conclude that the developed formulation is effective with improved efficacy, promised release and patient compliance.